China's first "antibody drug coupled treatment of malignant tumor clinical application expert consensus" issued...

On December 5, China's first "Consensus of Experts on Clinical Application of Antibody Drug Associations for the Treatment of Malignant Tumors" was released at the National Cancer Center Clinical Research Summit Forum and the Academic Annual Meeting of the Clinical Research Committee of the Chinese Cancer Society.
The consensus was developed by nearly 60 of the country's leading malignant tumor clinical specialists and interdisciplinary clinical experts, with the aim of providing a systematic overview of the antibody-drug conjugate (ADC) drugs available on the market, thus providing effective advice and reference for clinicians to better apply and manage ADC drugs and advancing clinical research progress on ADC drugs.
(left to right: Wang Jiayu, Ma Fei, Xu Binghe, Li Guohui, Li Man, Mei Zhihong) ADC drugs are a class of targeted biological agents that are coupled with antibodies, linked to and effect molecules, and are designed to Specific monoclonal antibodies are coupled with highly lethal cytotoxins, so that monoantigens as vectors to target small molecules of high-efficiency cytotoxins to target tumor cells, compared to traditional chemotherapy drugs have a better targeting effect, compared to traditional antibody drugs have a better tumor killing effect.
In response, Professor Ma Fei, Deputy Director of Internal Medicine, Oncology Hospital, Chinese Academy of Medical Sciences, explained: "First, ADC drugs can target tumors more specifically by conceding, which can reduce the effective dose required to kill tumors, thereby reducing the toxicity of chemotherapy drugs;
" at the same time, professor Li Guohui, director of the Pharmacy Department of the Oncology Hospital of the Chinese Academy of Medical Sciences, added: "Compared to individual chemotherapy drugs, ADC drug adverse reactions are much lower, from the clinical efficacy point of view, played a role in efficiency reduction."
" In recent years, ADC drug research and development has made a breakthrough, the world has approved eight ADC drugs, while hundreds of ADC drugs clinical research is under way, according to Fudan University Affiliated Oncology Hospital Vice President Professor Ye Dingwei, approved drugs Adaptive disorders, including leukemia, lymphoma, breast cancer, stomach cancer, urethra cancer, etc., provide potential therapeutic effects and survival benefits in other solid tumors, such as prostate cancer, lung cancer, etc., these drugs are currently in clinical trials and may benefit these patients in the future.
predictable is that a large number of ADC drugs will be used in clinical applications in the future.
(left to right: Li Guohui, Ma Fei, Xu Binghe, Wang Jiayu) in 2020 the first domestic approval of two ADC drugs on the market, ushering in the chinese ADC new year.
One of them is the Trastuzumab Emtansine (T-DM1), which was approved in January this year, which is the first antibody-coupled drug approved in China, filling the treatment gap of HER2-positive breast cancer patients in China who have not yet reached the complete pathological remission after the new auxiliary treatment.
According to Professor Wang Jiayu of the Oncology Hospital of the Chinese Academy of Medical Sciences, "T-DM1 has become the gold standard for second-line treatment of HER2-positive advanced breast cancer, which is significantly improved in efficacy and adverse reactions compared to the previous Rapatini joint Capathamin program, and brings benefits and benefits to more than 25% of HER2-positive breast cancer second-line and backline patients."
special mechanism and dosage form structure of T-DM1 make its pharmacological effect more targeted, the cytotoxic effect plays better, and indeed improves the efficacy a lot.
" other drug is vibutoxidan, approved by the State Drug Administration in May this year for the treatment of relapsed or refractory sALCL and relapsed or refractory CHL.
, the clinical application of ADC drugs and their clinical development still face many challenges.
Professor Xu Binghe, Director of the Clinical Research Center for New Drugs (Anti-Tumor) at the National Cancer Center of the Chinese Academy of Medical Sciences, said that because ADC drugs do not appear for a long time, there are still questions about their application, mechanism of action and side effects, especially how to deal with them, and there is an urgent need for a consensus to guide their clinical application.
, "Antibody drug association treatment of malignant tumor clinical application expert consensus" came into being.
It is understood that although there are data showing that ADC drugs have good clinical efficacy and tolerance, but most ADC drugs are still in clinical trial stage, in order to make this new drug earlier for the benefit of cancer patients, this consensus also considered that some are still in the clinical research stage, but already has some clinical evidence of ADC drugs into it to promote its clinical research progress.
。